Literature DB >> 16449261

Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients.

E Truyen1, L Coteur, E Dilissen, L Overbergh, L J Dupont, J L Ceuppens, D M A Bullens.   

Abstract

BACKGROUND: Asthma is a chronic inflammatory disorder of the airways driven by T cell activation. Th2 cells and their cytokines are thought to play a role in the pathophysiology of allergic as well as non-allergic asthma.
METHODS: Airway cells were obtained by sputum induction from 15 healthy and 39 asthmatic individuals and the airway T cell cytokine profiles (interleukin (IL)-4, IL-5, IL-13, IL-10 and interferon (IFN)-gamma) at the mRNA level were studied by real time RT-PCR.
RESULTS: Asthma patients had increased expression of IL-5 (p = 0.001) and IL-13 (p = 0.03) mRNA in sputum compared with non-asthmatic controls. IL-4 mRNA and IFN-gamma mRNA were detectable in the sputum of 44% and 21% of patients, respectively, but not in controls. Sputum IL-10 mRNA levels did not differ significantly between patients and controls. Sputum mRNA expression levels of IL-4, IL-5, and IL-13 were significantly correlated with the percentage of eosinophils and were higher in subjects with allergic asthma than in those with non-allergic asthma (p = 0.03, p = 0.02 and p = 0.0002, respectively); they did not differ between mild asthmatic subjects and those with moderate to severe asthma. In contrast, IFN-gamma mRNA expression was higher in non-allergic than in allergic patients (p = 0.04) and higher in patients with moderate to severe asthma than in those with mild asthma (p<0.01). Sputum IL-5 mRNA levels (but not the other cytokine mRNA levels) were also correlated with exhaled nitric oxide (eNO) and with bronchial hyperreactivity expressed as the histamine concentration resulting in a 20% decrease in forced expiratory volume in 1 second.
CONCLUSION: Real time RT-PCR analysis of mRNA in induced sputum confirms a predominance of Th2 cytokines in both allergic and non-allergic asthma. IL-5 levels reflect eosinophil infiltration as well as eNO levels and hyperreactivity, and levels of the Th1 cytokine IFN-gamma indicate asthma severity. The technique is a promising tool for use in further studies of asthma severity and disease activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16449261      PMCID: PMC2080739          DOI: 10.1136/thx.2005.052399

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  35 in total

Review 1.  An overview of real-time quantitative PCR: applications to quantify cytokine gene expression.

Authors:  A Giulietti; L Overbergh; D Valckx; B Decallonne; R Bouillon; C Mathieu
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Immunologic basis of antigen-induced airway hyperresponsiveness.

Authors:  M Wills-Karp
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

3.  Immuno-regulatory cytokines in asthma: IL-15 and IL-13 in induced sputum.

Authors:  M Komai-Koma; A McKay; L Thomson; C McSharry; G W Chalmers; F Y Liew; N C Thomson
Journal:  Clin Exp Allergy       Date:  2001-09       Impact factor: 5.018

4.  Basophil recruitment and IL-4 production during human allergen-induced late asthma.

Authors:  K T Nouri-Aria; A M Irani; M R Jacobson; F O'brien; E M Varga; S J Till; S R Durham; L B Schwartz
Journal:  J Allergy Clin Immunol       Date:  2001-08       Impact factor: 10.793

5.  Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma.

Authors:  M Humbert; S R Durham; P Kimmitt; N Powell; B Assoufi; R Pfister; G Menz; A B Kay; C J Corrigan
Journal:  J Allergy Clin Immunol       Date:  1997-05       Impact factor: 10.793

6.  Late response to allergen is associated with increased concentrations of tumor necrosis factor-alpha and IL-5 in induced sputum.

Authors:  V M Keatings; B J O'Connor; L G Wright; D P Huston; C J Corrigan; P J Barnes
Journal:  J Allergy Clin Immunol       Date:  1997-05       Impact factor: 10.793

Review 7.  Advances in mechanisms of allergy.

Authors:  Bruce S Bochner; William W Busse
Journal:  J Allergy Clin Immunol       Date:  2004-05       Impact factor: 10.793

8.  IL-4 and IL-5 mRNA expression in induced sputum of asthmatic subjects: comparison with bronchial wash.

Authors:  R Olivenstein; R Taha; E M Minshall; Q A Hamid
Journal:  J Allergy Clin Immunol       Date:  1999-02       Impact factor: 10.793

9.  Clinical implication of protein levels of IL-5 in induced sputum in asthmatic patients.

Authors:  S Shoji; H Kanazawa; K Hirata; N Kurihara; J Yoshikawa
Journal:  J Asthma       Date:  1998       Impact factor: 2.515

10.  Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation.

Authors:  G Hansen; G Berry; R H DeKruyff; D T Umetsu
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

View more
  56 in total

1.  Concordant modulation of cysteinyl leukotriene receptor expression by IL-4 and IFN-gamma on peripheral immune cells.

Authors:  S Brandon Early; Elizabeth Barekzi; Julie Negri; Kathleen Hise; Larry Borish; John W Steinke
Journal:  Am J Respir Cell Mol Biol       Date:  2007-02-01       Impact factor: 6.914

2.  Blockage of nerve growth factor modulates T cell responses and inhibits allergic inflammation in a mouse model of asthma.

Authors:  Yan Shi; Yingli Jin; Weiying Guo; Libo Chen; Chaoying Liu; Xiaohong Lv
Journal:  Inflamm Res       Date:  2012-08-08       Impact factor: 4.575

3.  A pilot study comparing T-regulatory cell function among healthy children in different areas of Gansu, China.

Authors:  Panhong Gou; Xiaoru Chang; Zhonghui Ye; Yueli Yao; Patton Khuu Nguyen; Sally Katharine Hammond; Junling Wang; Sa Liu
Journal:  Environ Sci Pollut Res Int       Date:  2017-08-14       Impact factor: 4.223

4.  High- and low-dose allergen challenges in asthmatic patients using inhaled corticosteroids.

Authors:  Wha-Yong Lee; Thomas Southworth; Steven Booth; Dave Singh
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

5.  IRF5 distinguishes severe asthma in humans and drives Th1 phenotype and airway hyperreactivity in mice.

Authors:  Timothy B Oriss; Mahesh Raundhal; Christina Morse; Rachael E Huff; Sudipta Das; Rachel Hannum; Marc C Gauthier; Kathryn L Scholl; Krishnendu Chakraborty; Seyed M Nouraie; Sally E Wenzel; Prabir Ray; Anuradha Ray
Journal:  JCI Insight       Date:  2017-05-18

Review 6.  Where asthma and hypersensitivity pneumonitis meet and differ: noneosinophilic severe asthma.

Authors:  Pieter Bogaert; Kurt G Tournoy; Thomas Naessens; Johan Grooten
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

7.  IL-13 Gene Polymorphisms are Associated With Rhinosinusitis and Eosinophilic Inflammation in Aspirin Intolerant Asthma.

Authors:  Nami Shrestha Palikhe; Seung-Hyun Kim; Bo-Young Cho; Gil-Soon Choi; Joo-Hee Kim; Young-Min Ye; Hae-Sim Park
Journal:  Allergy Asthma Immunol Res       Date:  2010-03-24       Impact factor: 5.764

8.  Obesity impairs apoptotic cell clearance in asthma.

Authors:  Ruby Fernandez-Boyanapalli; Elena Goleva; Christena Kolakowski; Elysia Min; Brian Day; Donald Y M Leung; David W H Riches; Donna L Bratton; E Rand Sutherland
Journal:  J Allergy Clin Immunol       Date:  2012-11-13       Impact factor: 10.793

9.  Early life exposure to environmental tobacco smoke alters immune response to asbestos via a shift in inflammatory phenotype resulting in increased disease development.

Authors:  Traci Ann Brown; Andrij Holian; Kent E Pinkerton; Joong Won Lee; Yoon Hee Cho
Journal:  Inhal Toxicol       Date:  2016-05-03       Impact factor: 2.724

10.  IL-13 expression by blood T cells and not eosinophils is increased in asthma compared to non-asthmatic eosinophilic bronchitis.

Authors:  Salman Siddiqui; Glenn Cruse; Susan McKenna; William Monteiro; Vijay Mistry; Andrew Wardlaw; Christopher Brightling
Journal:  BMC Pulm Med       Date:  2009-07-14       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.